Selskabets formål er at drive handel samt hermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1.5 mia. | 66.7 mio. | 298.3 mio. | 216.6 mio. | 23 | |
CVR: 20830131
Secondary names: LABKEMI DENMARK A/S, MILLIPORE A/S
Previous names: KM 156 A/S, LABKEMI DENMARK A/S, SIGMA-ALDRICH DENMARK ApS
Compared to 1.729 companies in Engroshandel med andre maskiner og andet udstyr
Comparison is based on industry median values
Merck Life Science A/S demonstrates a solid financial health with consistent revenue growth, increasing from 768 million DKK in 2020 to over 1.5 billion DKK in 2024. Profitability has remained relatively stable, with a slight dip in profit from 73.6 million DKK in 2023 to 66.7 million DKK in 2024, indicating potential margin pressures. The company's equity has decreased from 239.9 million DKK in 2023 to 216.6 million DKK in 2024, raising concerns about its financial stability. Overall, Merck Life Science A/S is positioned as a significant player in the machinery and equipment wholesale industry, benefiting from a robust revenue trajectory despite some challenges in profitability and equity.
AI-generated summary
Companies in the same industry and area
CVR 45848752
CVR 38548905
CVR 12478097
CVR 17198238
CVR 39692635
Janecke Stokkebokjær Lundring joined the board
Montserrat Jansa Rodriguez left the board
Janecke Stokkebokjær Lundring joined as ADM. DIR.
Montserrat Jansa Rodriguez left as ADM. DIR.
companydata.dk